Company intelligence / Profile preview

Xheme

Newton Center, Massachusetts, United Statesxhemeinc.com ↗

Ownership: Private
Development stage: Other

Overview

Xheme’s lead technology, the Multifunctional Additive (XMA), has demonstrated significant reduction or elimination of oxidative stress in bioprocessing conditions. Testing at UMASS Amherst showed up to 50% increase in cell proliferation and improved yields for biologics/cell therapeutics. The company is advancing toward commercialization with partners such as RENOLIT Healthcare and Vitalant Research Institute but remains pre-commercial as of mid 2025.

Therapeutic areas: HematologyOther
Modalities: Polymer composite additiveNanoporous polymer compositeMultifunctional additive
Industry: Chemicals & Materials

Partnerships

RENOLIT Healthcare (medical-grade polymeric films)Vitalant Research Institute (blood bag innovation)University of Bologna

Beyond the preview

Go deeper on Xheme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xheme.

Explore the full profile